Evidence map›Paper›PMID 41350281›Full record

ArticleNPJ biofilms and microbiomes2025

Identification of ferredoxin PA1551 as an antibacterial synergistic target for biofilm inhibitors against Pseudomonas aeruginosa.

Jun Liu, Anmin Ren, Zhiying Miao, Tian Zhou, Chenhui Zhang, Yiqun Chang, Siyu Zhao, Xibing Hu, Xiaoyi Zhang, Tianyuan Jia and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ biofilms and microbiomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jun Liu *State Key Laboratory of Bioactive Molecules and Druggability Assessment, College of Pharmacy, Institute for Advanced and Applied Chemical Synthesis, Jinan University, Guangzhou, PR China. liujun__jnu@163.com.
Anmin Ren *College of Medicine, Southern University of Science and Technology, Shenzhen, PR China.
Zhiying MiaoState Key Laboratory of Bioactive Molecules and Druggability Assessment, College of Pharmacy, Institute for Advanced and Applied Chemical Synthesis, Jinan University, Guangzhou, PR China.
Tian ZhouCollege of Medicine, Southern University of Science and Technology, Shenzhen, PR China.
Chenhui ZhangCollege of Medicine, Southern University of Science and Technology, Shenzhen, PR China.
Yiqun ChangState Key Laboratory of Bioactive Molecules and Druggability Assessment, College of Pharmacy, Institute for Advanced and Applied Chemical Synthesis, Jinan University, Guangzhou, PR China.
Siyu ZhaoState Key Laboratory of Bioactive Molecules and Druggability Assessment, College of Pharmacy, Institute for Advanced and Applied Chemical Synthesis, Jinan University, Guangzhou, PR China.
Xibing HuState Key Laboratory of Bioactive Molecules and Druggability Assessment, College of Pharmacy, Institute for Advanced and Applied Chemical Synthesis, Jinan University, Guangzhou, PR China.
Xiaoyi ZhangState Key Laboratory of Bioactive Molecules and Druggability Assessment, College of Pharmacy, Institute for Advanced and Applied Chemical Synthesis, Jinan University, Guangzhou, PR China.
Tianyuan JiaCollege of Medicine, Southern University of Science and Technology, Shenzhen, PR China.
Zhao CaiCollege of Medicine, Southern University of Science and Technology, Shenzhen, PR China.
Zhengqiu LiState Key Laboratory of Bioactive Molecules and Druggability Assessment, College of Pharmacy, Institute for Advanced and Applied Chemical Synthesis, Jinan University, Guangzhou, PR China.
Jing LinState Key Laboratory of Bioactive Molecules and Druggability Assessment, College of Pharmacy, Institute for Advanced and Applied Chemical Synthesis, Jinan University, Guangzhou, PR China.
Liang YangCollege of Medicine, Southern University of Science and Technology, Shenzhen, PR China. yangl@sustech.edu.cn.
Weimin ChenState Key Laboratory of Bioactive Molecules and Druggability Assessment, College of Pharmacy, Institute for Advanced and Applied Chemical Synthesis, Jinan University, Guangzhou, PR China. twmchen@jnu.edu.cn.

Funding

National Natural Science Foundation of China 82173651National Natural Science Foundation of China 82473788
6 · The paper itself

Abstract

Addressing antibiotic-resistant bacterial biofilm infections without promoting drug resistance is a pressing challenge. Pseudomonas aeruginosa is well known for causing biofilm-associated drug-resistant infections that often lead to treatment failure. In this study, we identified a previously uncharacterized membrane protein ferredoxin encoded by PA1551 using photoaffinity-based biomimetic probes based on our previous dual-acting antibiofilm compound 2-(heptanamido)methyl 3-hydroxy-1,6-dimethylpyridin-4(1H)-one (10d). The precision-targeted ferredoxin PA1551 exhibited excellent effectiveness in various model systems, suppressing bacterial biofilm and virulence, and enhancing the antibacterial effects of tobramycin (Tob, by about 200-fold) and ciprofloxacin (CIP, by 1000-fold) compared to single-dose antibiotic treatments in a mouse model of Pseudomonas aeruginosa wound infection. These results indicate that ferredoxin PA1551 can be used as target to design new antibiofilm drugs for the treatment of Pseudomonas aeruginosa infections, particularly challenging bacterial biofilms.

Indexed as

Anti-Bacterial AgentsBiofilmsFerredoxinsPseudomonas aeruginosaAnimalsBacterial ProteinsCiprofloxacinDisease Models, AnimalDrug SynergismMiceMicrobial Sensitivity TestsPseudomonas InfectionsTobramycinWound InfectionAnti-Bacterial AgentsBacterial ProteinsCiprofloxacinFerredoxinsTobramycin

Identifiers

PMID41350281
PMCPMC12775422

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.